RAPP (Rapport Therapeutics) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics NonCurrent Deferred Liabilities?

Rapport Therapeutics RAPP -0.60% 14 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Rapport Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Rapport Therapeutics NonCurrent Deferred Liabilities Related Terms

Rapport Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics NonCurrent Deferred Liabilities Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Rapport Therapeutics (RAPP) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' NonCurrent Deferred Liabilities too high?
Rapport Therapeutics' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' NonCurrent Deferred Liabilities compare to SION and TYRA?
Rapport Therapeutics' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price